Budgetary impact of incorporating intermittent glucose moni toring for individuals with type 1 diabetes
PDF - Inglês (English)

Palavras-chave

Type 1 diabetes mellitus; Analysis of the Budgetary Impact of Therapeutic Advances; Blood Glucose Self-Monitoring

Como Citar

Carneiro de Freitas Nakata, K., Yugi Nakata, G., & Guenkka, T. M. (2025). Budgetary impact of incorporating intermittent glucose moni toring for individuals with type 1 diabetes. JORNAL DE ASSISTÊNCIA FARMACÊUTICA E FARMACOECONOMIA, 9(4). https://doi.org/10.22563/2525-7323.2024.v9.n.4.p.27-34e

Resumo

Objective: to evaluate the potential budgetary impact – BI resulting from the incorpora
tion of the FreeStyle® intermittent glucose monitoring system for individuals with type 1
diabetes mellitus – DM1. Methods: analyzes were carried out using the Excel application
for a time horizon of 5 years from the perspective of the state of Mato Grosso, Brazil. The
eligible population, individuals aged 18 or over with DM1 and severe hypoglycemia, was
selected with the help of an evidence synthesis. The assumed diffusion rates for years
1 to 5 were: 27%; 30%; 33%; 36% and 40%, respectively based on the frequency
with which Brazilian diabetics monitor their glucose; in the acceptance of technology
and the proportion of diabetic people with access to consultation and exams. A biva
riate sensitivity analysis was performed by modifying the population and implantation
rate parameters simultaneously. A scenario using smartphones to replace readers was
simulated. Results: The eligible population was 2,522 individuals with an increase of
2.6% in subsequent years. The annual cost for sensors/individual was R$7,774.00 and
for the reader R$299.00/individual for the entire time horizon. In years 1 and 5 the
BI was R$5,497,228.62 and R$8,712,561.00, respectively. Replacing readers with
smartphones did not prove to be significant for the period considered. Conclusions: the
BI of a possible incorporation of FreeStyle® is significant when compared to the amount
of budgetary resources reserved to operationalize the entire pharmaceutical assistance
policy in the state of Mato Grosso, Brazil.

https://doi.org/10.22563/2525-7323.2024.v9.n.4.p.27-34e
PDF - Inglês (English)
Creative Commons License
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.

Copyright (c) 2024 Kelli Carneiro de Freitas Nakata, Gilson Yugi Nakata, Ternize Mariana Guenkka